Attovia Therapeutics, Inc.
NASDAQ:ATTOBiotechnology
-$0.18 today
- Market cap
- $709.92M
- Beta
- 0.00
- P/E (TTM)
- -15.9
- EPS (TTM)
- -$0.86
Volume 0.34M
Average 0.45M
Balance Sheet
Inspect the capital base behind the business.
Assets
$165.89M
FY 2025 · Annual
+116.2% YoYLiabilities
$15.10M
FY 2025 · Annual
+3.5% YoYEquity
$150.79M
FY 2025 · Annual
+142.7% YoYBalance Sheet
Metric | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|
| Cash & Equivalents | 30.63M | 40.19M |
| Short-term Investments | 38.69M | 112.08M |
| Net Receivables | 0 | 0 |
| Inventory | 0 | 0 |
| Other Current Assets | 3.16M | 4.03M |
| Total Current Assets | 72.48M | 156.3M |
| Property, Plant & Equipment (Net) | 3.23M | 7.87M |
| Goodwill | 0 | 0 |
| Intangible Assets | 0 | 0 |
| Long-term Investments | 607K | 404K |
| Tax Assets | 0 | 0 |
| Other Non-current Assets | 393K | 1.33M |
| Total Non-current Assets | 4.23M | 9.6M |
| Total Assets | 76.72M | 165.89M |
| Account Payables | 4.14M | 3.55M |
| Short-term Debt | 0 | 1.92M |
| Tax Payables | 0 | 0 |
| Deferred Revenue | 0 | 450K |
| Other Current Liabilities | 1.52M | 1.98M |
| Total Current Liabilities | 7.72M | 11.01M |
| Long-term Debt | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 |
| Other Non-current Liabilities | 6.87M | 755K |
| Total Non-current Liabilities | 6.87M | 4.1M |
| Total Liabilities | 14.59M | 15.1M |
| Common Stock | 1K | 1K |
| Retained Earnings | (50.38M) | (111.01M) |
| Accumulated OCI | 67K | 99K |
| Other Stockholders Equity | 0 | 0 |
| Minority Interest | 0 | 0 |
| Total Equity | 62.13M | 150.79M |
| Total Debt | 0 | 5.26M |
| Net Debt | (30.63M) | (34.93M) |
Balance Sheet
Assets, liabilities & equity
| Cash & Equivalents | $32.8M |
| Short-term Investments | $82.3M |
| Other Current | $3.3M |
| Total Current Assets | $118.4M |
| PP&E (Net) | $6.9M |
| Long-term Investments | $404.0K |
| Other Non-current | $2.6M |
| Total Non-current Assets | $9.9M |
| Total Assets | $128.3M |
Analysis
Selected assets total $128.3M for Latest. The largest visible component is Short-term Investments at $82.3M, about 64.1% of the tab total. Use the mix to judge balance sheet concentration, liquidity, leverage, and how much of book value is supported by tangible operating assets.
Competitors
Peer companies in the same sector
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| SC 13G | SC 13G filing | Nov 13, 2026 | |
| SC 13G | SC 13G filing | Nov 13, 2026 | |
| 8-K | Current report | Nov 9, 2026 | |
| 10-Q | Quarterly report | Nov 9, 2026 | |
| 3/A | 3/A filing | Oct 8, 2026 |
How much cash does ATTO have?
Attovia Therapeutics, Inc. (ATTO) reported $40.19M in cash and equivalents in fiscal 2025.
How much debt does ATTO carry?
Attovia Therapeutics, Inc. (ATTO) reported $5.26M of total debt, with net debt of -$34.93M.
Continue the stock analysis
Jump to another research area for this company.